Interna Technologies B.v.

Koninklijke Nederlandse Akademie Van Wetenschappen

Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg

Intera Technologies B.v.

Willemijn Maria Gommans

Roeland Quirinus Jozef Schaapveld

Eugene Berezikov

Rick Jan Van Haastert

Grégoire Pierre André Prevost

Sanne Weijzen

Petronella Innocentia Van Noort

Arjan Willem Griffioen

Meriem Bourajjaj

Andreas Alphons F L Van Puijenbroek

Andreas Alphons Franciscus Ludovicus Van Puijenbroek

Edwin Pieter Johan Gerard Cuppen

Negar Babae

Jos Bernard Poell

Jacobus Antonius Schalken

Matheus Maria De Gunst

Iman Johannes Schultz

Judith Rosina Van Beijnum

Rudolf Henrikus Brakenhoff

Gerardus Wilhelmus Christiaan Theodoor Verhaegh

Marlon Van Der Plas

Judith Rosina Van Biejnum

Andreas Alphons Franciscus Ludovicus Van Piujenbroek

Sanne Rosaly De Kemp

Francesco Cerisoli

Gregoire Pierre Prevost

Roeland Quirinus Schaapveld

Andreas Alphons Van Puijenbroek

Andreas Alphons Franciscus L Van Puijenbroek

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.

MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway

The invention relates to the therapeutic use of a combination in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.

Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway

The invention relates to the diagnostic and therapeutic uses of a miRNA-323, miRNA-342, miRNA-326, miRNA-371, miRNA-3157 and/or miRNA-345 molecule, an equivalent or a source thereof in a disease and condition associated with a squamous cell carcinoma such as head and neck cancer or a preneoplastic mucosal change.

MiRNA for treating head and neck cancer

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.

MiRNA for treating diseases and conditions associated with neo-angiogenesis

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule or an equivalent thereof wherein a source of said miRNA molecule or equivalent thereof comprises at least 80 nucleotides and comprises a motif having at least 98% identity with the motif represented by SEQ ID NO:1 or a source thereof in a disease and condition associated with EMT (Epithelial to Mesenchymal Transition).

MiRNA molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with EMT

Growing community of inventors

Voorschoten, Netherlands

Willemijn Maria Gommans